X0508 4 2025-12-08 0001730430 Kiniksa Pharmaceuticals International, plc KNSA 0001835458 Ragosa Mark C/O KINIKSA PHARMACEUTICALS INTERNATIONA 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ UNITED KINGDOM false true false false CHIEF FINANCIAL OFFICER 1 Class A Ordinary Share 2025-12-08 4 M 0 16164 11.10 A 47250 D Class A Ordinary Share 2025-12-08 4 M 0 16165 11.97 A 63415 D Class A Ordinary Share 2025-12-08 4 M 0 10512 10.76 A 73927 D Class A Ordinary Share 2025-12-08 4 S 0 42841 41.49 D 31086 D Share Option 11.10 2025-12-08 4 M 0 16164 0 D 2032-04-06 Class A Ordinary Share 16164 5388 D Share Option 11.97 2025-12-08 4 M 0 16165 0 D 2032-08-31 Class A Ordinary Share 16165 12123 D Share Option 10.76 2025-12-08 4 M 0 10512 0 D 2033-03-31 Class A Ordinary Share 10512 14016 D This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.20 and $42.08. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023. /s/ Douglas Barry, Attorney-in-Fact 2025-12-10